F
20.14
-0.24 (-1.20%)
| Previous Close | 20.38 |
| Volume | 494,854 |
| Price / Earnings (Forward) | 11.26 |
| Price / Sales | 0.760 |
| Price / Book | 3.88 |
| 52 Weeks Range |
| Profit Margin | -29.43% |
| Operating Margin (TTM) | -3.81% |
| Diluted EPS (TTM) | -8.39 |
| Quarterly Revenue Growth (YOY) | -1.60% |
| Total Debt/Equity (MRQ) | 149.92% |
| Current Ratio (MRQ) | 0.970 |
| Operating Cash Flow (TTM) | 164.20 M |
| Levered Free Cash Flow (TTM) | 310.66 M |
| Return on Assets (TTM) | -1.74% |
| Return on Equity (TTM) | -61.58% |
AIStockmoo Score
| Value 35% | -2.1 |
| AI Insight info | NA |
| Relative Valuation info | NA |
| Financial Health info | -2.1 |
| Timing 35% | 0.7 |
| AI Technical info | NA |
| Technical Oscillators info | -0.5 |
| Technical Moving Averages info | 2.5 |
| Smart Money 30% | 0.0 |
| Analyst Consensus info | 0.0 |
| Insider Activity info | NA |
| News Mood info | NA |
| Environment | ×1.21 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | -23.0% |
| Pillar Agreement | ×1.00 |
| Not in score | |
| Price Volatility info | -4.7 |
| Final Score | -0.59 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Fortrea Holdings Inc. | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| FTRE | - | - | - | 3.88 |
| TRML | 1 B | - | - | 4.76 |
| ABEO | - | - | - | 1.04 |
| CTNM | - | - | - | 1.69 |
| DBVT | - | - | - | 4.87 |
| JANX | - | - | - | 0.810 |
Select this tab to load the latest available analysis.
|
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.40% |
| % Held by Institutions | 101.90% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 31 Oct 2026 | Yahoo Finance |
FTRE Q3 deep dive: margin gains, backlog reset, and early-phase expansion shape outlook
Clinical research company Fortrea Holdings (NASDAQ:FTRE) reported Q3 2026 results beating Wall Street’s revenue expectations, but sales fell by 1.4% year on year to $691.5 million. The company’s full-year revenue guidance of $2.68 billion at the midpoint came in 0.5% above analysts’ estimates. Its… |
| 31 Oct 2026 | Yahoo Finance |
Earnings Beat Could Reset The Case For Fortrea Stock
Fortrea Holdings reported Q3 2026 revenue of US$691.5 million and returned to a modest profit, while also narrowing and raising full year 2026 revenue guidance to a range of US$2.665 billion to US$2.69 billion. The acquisition of Worldwide Clinical Trials' Early Phase Services business expands… |
| 30 Oct 2026 | Yahoo Finance |
Fortrea Holdings Inc. Q3 2026 Earnings Call Summary
Moby summary of Fortrea Holdings Inc.'s Q3 2026 earnings call… |
| 30 Oct 2026 | Yahoo Finance |
Fortrea Holdings (FTRE) Stock Sees Modest Fair Value Lift As Margin Views Improve
Fortrea Holdings now carries a modestly higher fair value estimate, moving from US$20.55 to US$21.71 per share, as analysts refresh their models. Behind this change, recent commentary shows bulls and bears debating how current margins, revenue visibility, and execution risks line up with where the… |
| 30 Oct 2026 | Yahoo Finance |
Fortrea (FTRE) Stock Drops After Q3 Results Lift Guidance
Fortrea came into this Q3 2026 report with a stock that had quietly rebuilt some confidence over the past three months, only to see that mood crack with a one day slide of almost 8% to US$21.29. The CRO specialist has been treated as a long duration recovery story, but the headline this quarter is… |
| 29 Oct 2026 | Yahoo Finance |
Fortrea (FTRE) Q3 2026 Earnings Call Transcript
Adjusted EBITDA surged 14.4% on portfolio mix and cost discipline. |
| 29 Oct 2026 | Yahoo Finance |
Fortrea Holdings Inc. (FTRE) Q3 Earnings and Revenues Surpass Estimates
Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of +16.67% and +3.18%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 29 Oct 2026 | Yahoo Finance |
What Fortrea (FTRE) Said on Its Q3 Earnings Call
Fortrea (NASDAQ:FTRE) reported third-quarter 2026 revenue of $691.5 million, down 1.4% from a year earlier but up 2.0% sequentially, as the contract research organization cited improving demand, stronger operational execution and continued cost discipline. Adjusted EBITDA totaled $58.0 million, ris… |
| 29 Oct 2026 | Yahoo Finance |
Fortrea (NASDAQ:FTRE) surprises with strong Q3 2026
Clinical research company Fortrea Holdings (NASDAQ:FTRE) announced better-than-expected revenue in Q3 2026, but revenue fell by 1.4% year on year to $691.5 million. The company’s full-year revenue guidance of $2.68 billion at the midpoint came in 0.5% above analysts’ consensus estimates. Its… |
| 29 Oct 2026 | Yahoo Finance |
Fortrea Reports Third Quarter 2026 Results
Sustained commercial momentum, continued margin improvement, and targeted investments strengthen growth foundationHighlights For the three months ended September 30, 2026: Revenues of $691.5 millionBook-to-bill ratio of 1.12x, resulting in 1.12x book-to-bill for the trailing 12 monthsGAAP net… |
| 28 Oct 2026 | Yahoo Finance |
Earnings to watch: Fortrea (FTRE) reports Q3 results tomorrow
Clinical research company Fortrea Holdings (NASDAQ:FTRE) will be announcing earnings results this Thursday before the bell. Here’s what to expect. |
| 27 Oct 2026 | Yahoo Finance |
Fortrea to Participate in Jefferies Global Healthcare Conference
DURHAM, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations Tracy Krumme will participate in the following conference: Jefferies Global… |
| 26 Oct 2026 | Yahoo Finance |
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
| 26 Oct 2026 | Yahoo Finance |
3 unpopular stocks that concern us
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth. |
| 23 Oct 2026 | Yahoo Finance |
This Stock Is Hot at New 52-Week Highs. But It Now for Profit Growth Ahead.
Fortrea (FTRE) demonstrates robust technical momentum, recently hitting a new 52-week high. Shares are up nearly 120% over the past year. FTRE maintains a 100% “Buy” technical opinion from Barchart. I view FTRE as a compelling opportunity due to its attractive valuation, strong growth prospects… |
| 22 Oct 2026 | Yahoo Finance |
Fortrea Holdings Inc. (FTRE) Earnings Expected to Grow: Should You Buy?
Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
| 22 Oct 2026 | Yahoo Finance |
Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development
Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in AustraliaHighlights Collaboration aims to accelerate precision oncology research in AustraliaCombines Fortrea’s experience in oncology clinical trials with Omico’s Precision Oncology Screening… |
| 19 Oct 2026 | Yahoo Finance |
Fortrea Completes Acquisition of the Early Phase Services Division from Worldwide Clinical Trials
Expands Fortrea’s early clinical development network with dedicated bioanalytical capabilities, increased clinical research unit capacity and a more integrated platform for clientsHighlights Fortrea completes acquisition of the Early Phase Services division from Worldwide Clinical TrialsAdds a… |
| 19 Oct 2026 | Yahoo Finance |
Is Fortrea Holdings (FTRE) Still Cheap After Its 116% Run?
Fortrea Holdings has delivered a sharp share price run, and the question now is whether the cash the business can generate really supports where the stock trades today. After a year of strong gains and a brighter narrative around its operations, investors are increasingly focused on what the… |
| Show more | ||
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |